New Trends in the Diagnosis and Therapy of Non-Alzheimer’s Dementia: Journal of Neural Transmission. Supplementa, cartea 47
Editat de Kurt A. Jellinger, Manfred Windischen Limba Engleză Paperback – 16 iul 1996
Din seria Journal of Neural Transmission. Supplementa
- 5% Preț: 481.82 lei
- 5% Preț: 1052.61 lei
- 5% Preț: 407.20 lei
- Preț: 375.23 lei
- 5% Preț: 347.31 lei
- 5% Preț: 685.67 lei
- 5% Preț: 351.89 lei
- Preț: 365.43 lei
- 5% Preț: 362.28 lei
- Preț: 366.17 lei
- 15% Preț: 640.55 lei
- 5% Preț: 990.01 lei
- 5% Preț: 354.88 lei
- 5% Preț: 359.80 lei
- Preț: 376.53 lei
- 15% Preț: 619.01 lei
- Preț: 367.27 lei
- 5% Preț: 379.50 lei
- 5% Preț: 360.69 lei
- Preț: 383.02 lei
- 5% Preț: 350.65 lei
- 5% Preț: 358.94 lei
- 5% Preț: 358.21 lei
- 5% Preț: 372.48 lei
- 5% Preț: 367.71 lei
- 5% Preț: 353.67 lei
- 5% Preț: 698.36 lei
- 18% Preț: 1347.23 lei
- 5% Preț: 1314.97 lei
- 5% Preț: 1374.51 lei
- 5% Preț: 1054.21 lei
- 5% Preț: 687.46 lei
- 5% Preț: 1070.93 lei
- 5% Preț: 1015.42 lei
- 5% Preț: 692.53 lei
- 5% Preț: 1381.89 lei
- 5% Preț: 1304.04 lei
- 5% Preț: 1980.17 lei
Preț: 365.07 lei
Preț vechi: 384.29 lei
-5% Nou
Puncte Express: 548
Preț estimativ în valută:
69.87€ • 73.89$ • 58.28£
69.87€ • 73.89$ • 58.28£
Carte tipărită la comandă
Livrare economică 30 decembrie 24 - 13 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783211828236
ISBN-10: 3211828230
Pagini: 300
Ilustrații: VIII, 288 p. 24 illus.
Dimensiuni: 210 x 279 x 16 mm
Greutate: 0.68 kg
Editura: SPRINGER VIENNA
Colecția Springer
Seria Journal of Neural Transmission. Supplementa
Locul publicării:Vienna, Austria
ISBN-10: 3211828230
Pagini: 300
Ilustrații: VIII, 288 p. 24 illus.
Dimensiuni: 210 x 279 x 16 mm
Greutate: 0.68 kg
Editura: SPRINGER VIENNA
Colecția Springer
Seria Journal of Neural Transmission. Supplementa
Locul publicării:Vienna, Austria
Public țintă
ResearchCuprins
Structural basis of dementia in neurodegenerative disorders.- Cytoskeletal pathology in non-Alzheimer degenerative dementia: new lesions in Diffuse Lewy body disease, Pick’s disease, and Corticobasal Degeneration.- The neuropathologic diagnostic criteria of frontal lobe dementia revisited. A study of ten consecutive cases.- Cognitive deficits in non-Alzheimer’s degenerative diseases.- The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared.- Clinical features of frontal lobe dementia in comparison to Alzheimer’s disease.- Frontal lobe dementia and motor neuron disease.- Clinical and pathological characteristics of primary progressive aphasia and frontal dementia.- MR-imaging of non-Alzheimer’s dementia.- Functional imaging techniques in the diagnosis of non-Alzheimer dementias.- Quantitative EEG in frontal lobe dementia.- Vascular dementia: perfusional and metabolic disturbances and effects of therapy.- The spectrum of depressive pseudo-dementia.- Molecular biology of APO E alleles in Alzheimer’s and non-Alzheimer’s dementias.- Transmissible cerebral amyloidosis.- Human prion diseases.- The survival response of mesencephalic dopaminergic neurons to the neurotrophins BDNF and NT-4 requires priming with serum: comparison with members of the TGF-? superfamily and characterization of the serum-free culture system.- Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer’s disease: impact on non-Alzheimer’s dementia?.- Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin®.- Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides.- Cerebrolysin® protects neurons from ischemia-induced loss of microtubule — associatedprotein 2.- The long-term effect of NGF, b-FGF and Cerebrolysin® on the spatial memory after fimbria-fornix lesion in rats.- The influence of Cerebrolysin® and E021 on spatial navigation of young rats.- Effects of Cerebrolysin® on cytoskeletal proteins after focal ischemia in rats.- The short-term influence of b-FGF, NGF and Cerebrolysin® on the memory impaired after fimbria-fornix lesion.- Brain tissue hydrolysate, Cerebrolysin®, acts on presynaptic adenosine receptors in the rat hippocampus.